http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 주제어 : 프로그램된 세포사멸 수용체-1 (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
김하나,조선욱,박영주 대한갑상선학회 2019 International Journal of Thyroidology Vol.12 No.2
Cancer immunotherapy has emerged as a promising therapy for a wide variety of tumors. Immune checkpoint inhibitors including anti cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed death 1 (PD-1) and programmed death ligand-1 (PD-L1) monoclonal antibodies have proven to be especially effective in various advanced cancers. However, cancer the immunotherapy disturbs the immune system and may also cause immune related side effects (IRAE) distinguished from cytotoxic chemotherapy toxicity. Among them, endocrine IRAE has been reported with a higher incidence than other organ IRAE. We focus on the most relevant and new aspects related to endocrine IRAE due to cancer immunotherapy in this review.
-
F-157 Clinical characteristics of lung cancer with programmed death-ligand 1 expression
박하영,양옥미,고희지,고보건,장진선,김태옥,신홍준,박철규,임정환,권용수,오인재,김유일,임성철,김영철,최유덕 대한결핵 및 호흡기학회 2017 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.124 No.0
Background: Programmed death-ligand 1 (PD-L1) is a transmembrane protein that binds to the programmed death-1 (PD-1) receptor and anti-PD-1 therapy enables the immune response against tumors. The aim of this study was to assess the clinical and pathological characteristics of PD-L1 positive lung cancer. Methods: We retrospectively reviewed the medical record of pathologically proven lung cancer patients, and collected 267 cases of formalin-fixed, paraffin-embedded tissue sample from single institution. PD-L1 expression was detected by qualitative immunohistochemistry using Monoclonal Mouse Anti-PD-L1, Clone 22C3 and determined by using Tumor Proportion Score (TPS), which is the percentage of viable tumor cells showing partial or complete membrane staining. Results: A total of 267 patients were enrolled and major histologic type was adenocarcinoma (69.3%). Most were smoker (67.4%) and clinical stage IV (60.7%) with 31 (11.6%) cases of EGFR mutation and 17 (6.4%) cases of ALK rearrangement. The patients who showed TPS ≥ 1% and 50% were 116 (42%) and 58 (21%), respectively. TPS ≥ 1% group was older than TPS < 1% group (64.83±9.38 vs. 61.73±10.78, p=0.014). In histological grade, the proportion of poorly differentiated tumor was significantly higher in PD-L1 positive than negative group (40.8% vs. 25.8% based on TPS ≥ 1%, p=0.020 and 53.2% vs. 27.2% based on TPS ≥ 50%, p=0.004). But there was no difference in smoking, histologic type, EGFR or ALK status between two groups. Conclusions: PD-L1 expression was observed more frequently in poorly differentiated grade lung cancer.
KCI
KISS연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
